Pharmaceutical Following the recent US Food and Drug Administration approval of Spravato (esketamine) nasal spray, from US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen Pharmaceuticals unit, GlobalData’s pharma analyst Alessio Brunello, says that the drug “has the potential to make a significant impact on the treatment of many major depressive disorder (MDD) patients who have been unresponsive to current antidepressant therapy, as none of the previous marketed products for depression can demonstrate rapid antidepressant effects.” 24 May 2019